Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Contemporary national trends in prostate cancer risk profile at diagnosis.

Fletcher SA, von Landenberg N, Cole AP, Gild P, Choueiri TK, Lipsitz SR, Trinh QD, Kibel AS.

Prostate Cancer Prostatic Dis. 2019 Jun 24. doi: 10.1038/s41391-019-0157-y. [Epub ahead of print]

PMID:
31235801
2.

Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 May.

3.

A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.

Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, Carroll PR.

Eur Urol. 2014 Sep;66(3):550-60. doi: 10.1016/j.eururo.2014.05.004. Epub 2014 May 16.

4.

Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.

Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasarainen H, Bangma CH, Schröder FH, Roobol MJ.

BJU Int. 2012 Dec;110(11):1672-7. doi: 10.1111/j.1464-410X.2012.11434.x. Epub 2012 Aug 29.

5.

Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.

Buzzoni C, Auvinen A, Roobol MJ, Carlsson S, Moss SM, Puliti D, de Koning HJ, Bangma CH, Denis LJ, Kwiatkowski M, Lujan M, Nelen V, Paez A, Randazzo M, Rebillard X, Tammela TL, Villers A, Hugosson J, Schröder FH, Zappa M.

Eur Urol. 2015 Nov;68(5):885-90. doi: 10.1016/j.eururo.2015.02.042. Epub 2015 Mar 16.

6.

Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE).

Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR; CaPSURE.

J Urol. 2003 Dec;170(6 Pt 2):S21-5; discussion S26-7. Erratum in: J Urol. 2004 Feb;171(2 Pt 1):811.

PMID:
14610406
7.

Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.

Kelly SP, Anderson WF, Rosenberg PS, Cook MB.

Eur Urol Focus. 2018 Jan;4(1):121-127. doi: 10.1016/j.euf.2017.10.014. Epub 2017 Nov 20.

8.

Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.

Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV.

Eur Urol. 2014 Jan;65(1):177-85. doi: 10.1016/j.eururo.2012.08.070. Epub 2012 Sep 7.

PMID:
22981136
9.

Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2007 and 2013: status from a Danish primary referral center.

Thomsen FB, Mikkelsen MK, Hansen RB, Krug AH, Glenthøj A, Stattin P, Brasso K.

Acta Oncol. 2016 Dec;55(12):1456-1460. Epub 2016 Jun 22.

PMID:
27333339
10.

Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.

Tosoian JJ, Chappidi M, Feng Z, Humphreys EB, Han M, Pavlovich CP, Epstein JI, Partin AW, Trock BJ.

BJU Int. 2017 May;119(5):676-683. doi: 10.1111/bju.13573. Epub 2016 Jul 29.

11.

Very-high-risk localized prostate cancer: definition and outcomes.

Sundi D, Wang VM, Pierorazio PM, Han M, Bivalacqua TJ, Ball MW, Antonarakis ES, Partin AW, Schaeffer EM, Ross AE.

Prostate Cancer Prostatic Dis. 2014 Mar;17(1):57-63. doi: 10.1038/pcan.2013.46. Epub 2013 Nov 5.

12.

Diagnostic characteristics of lethal prostate cancer.

Helgstrand JT, Røder MA, Klemann N, Toft BG, Brasso K, Vainer B, Iversen P.

Eur J Cancer. 2017 Oct;84:18-26. doi: 10.1016/j.ejca.2017.07.007. Epub 2017 Aug 2.

PMID:
28779631
13.

Increasing detection of significant prostate cancer in younger men - ten year trends in prostate cancer risk profile in the Mid-West of Ireland.

Bhatt NR, Kelly T, Domanska K, Fogarty C, Durkan G, Flood HD, Giri SK.

Cent European J Urol. 2017 Jun 30;70(2):143-147. doi: 10.5173/ceju.2017.1361. Epub 2017 Jun 10.

14.

Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.

Assel M, Dahlin A, Ulmert D, Bergh A, Stattin P, Lilja H, Vickers AJ.

Eur Urol. 2018 Jun;73(6):961-967. doi: 10.1016/j.eururo.2017.10.004. Epub 2017 Oct 21.

15.

Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database.

Bandini M, Mazzone E, Preisser F, Nazzani S, Zaffuto E, Marchioni M, Tian Z, Pompe RS, Tilki D, Graefen M, Shariat SF, Montorsi F, Saad F, Briganti A, Karakiewicz P.

Eur Urol Oncol. 2018 Sep;1(4):314-320. doi: 10.1016/j.euo.2018.04.013. Epub 2018 May 15.

PMID:
31100253
16.

Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.

Gnanapragasam VJ, Lophatananon A, Wright KA, Muir KR, Gavin A, Greenberg DC.

PLoS Med. 2016 Aug 2;13(8):e1002063. doi: 10.1371/journal.pmed.1002063. eCollection 2016 Aug.

17.

Changing Incidence of Metastatic Prostate Cancer by Race and Age, 1988-2015.

Dall'Era MA, deVere-White R, Rodriguez D, Cress R.

Eur Urol Focus. 2018 May 4. pii: S2405-4569(18)30106-8. doi: 10.1016/j.euf.2018.04.016. [Epub ahead of print]

PMID:
29735368
18.

A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.

Van Den Eeden SK, Lu R, Zhang N, Quesenberry CP Jr, Shan J, Han JS, Tsiatis AC, Leimpeter AD, Lawrence HJ, Febbo PG, Presti JC.

Eur Urol. 2018 Jan;73(1):129-138. doi: 10.1016/j.eururo.2017.09.013. Epub 2017 Oct 6.

PMID:
28988753
19.

Prostate cancer incidence and newly diagnosed patient profile in Spain in 2010.

Cózar JM, Miñana B, Gómez-Veiga F, Rodríguez-Antolín A, Villavicencio H; 25 Urology Units, Asociación Española de Urología, Cantalapiedra A, Pedrosa E.

BJU Int. 2012 Dec;110(11 Pt B):E701-6. doi: 10.1111/j.1464-410X.2012.11504.x. Epub 2012 Sep 19.

20.

Patterns of care and treatment trends for Canadian men with localized low-risk prostate cancer: an analysis of provincial cancer registry data.

Tran K, Rahal R, Fung S, Louzado C, Porter G, Xu J, Bryant H; Collaboration with the System Performance Steering Committee and Technical Working Group.

Curr Oncol. 2016 Feb;23(1):56-9. doi: 10.3747/co.23.3011. Epub 2016 Feb 18.

Supplemental Content

Support Center